Correction: STRA6 polymorphisms are associated with EGFR mutations in locally-advanced and metastatic non-small cell lung cancer patients
Saé Muñiz-Hernández, Jesús Bernardino Velázquez-Fernández, José Díaz-Chávez, Omar Mondragón-Fonseca, Yerye Mayén-Lobo, Alberto Ortega, Marisol López-López, Oscar Arrieta
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsLung Cancer Treatments and Mutations · Effects of Radiation Exposure · Colorectal Cancer Treatments and Studies
In the published article, the legend of Figure 1 did not specify the meaning of the circles on the Kaplan–Meier curves.
The caption for Figure 1 has been updated to read:
“Kaplan–Meier curves for progression-free survival depending on rs974456 expression. Circles on the Kaplan–Meier curves represent censored observations.”
In the published article, the definition of progression-free survival (PFS) in the Statistical Analysis section was imprecise and could be interpreted as treating unacceptable toxicity and loss to follow-up as PFS events. In all survival analyses, however, PFS events consisted only of radiologic or clinical disease progression or death from any cause; patients who discontinued treatment due to unacceptable toxicity or were lost to follow-up were censored at the date of last disease assessment or last contact.
A correction has been made to the section Statistical Analysis, where the PFS definition previously read:
“PFS was defined as the time to an event from the date of initiating treatment until disease progression, unacceptable toxicity, death, or loss to follow-up.”
The corrected text now reads:
“Progression-free survival (PFS) was defined as the time from the date of initiating treatment to radiologic or clinical disease progression or death from any cause, whichever occurred first. Patients without progression or death, including those who discontinued treatment due to unacceptable toxicity or were lost to follow-up, were censored at the date of last disease assessment or last contact.”
The original version of this article has been updated.